Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Velesco Expands Operations with Massachusetts Office at the New QCI

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
Opening of new business development office in the greater Boston area.

Velesco Pharma has boosted its drug formulation, analytical development and cGMP clinical trial manufacturing services with the opening of a new business development office in the greater Boston area.

Velesco supports early stage drug development projects with a deeply experienced scientific team. Velesco is a CMC CRO, founded and staffed by pharmaceutical scientists with decades of experience in the industry.

“The growth of Velesco’s early phase CMC services has led to a need to increase our presence in this global hub for pharma and biotech companies. As we enter our 6th year of operations, we are looking forward to having a presence nearer to our existing and prospective clients,” said Gerry Cox, Velesco co-founder and chief operating officer, who will be leading the new office.

“In Massachusetts we invest in the life sciences because we are choosing to shape our own future,” said Governor Deval Patrick. “We welcome Velesco to Quincy’s new Innovation Center and look forward to them creating jobs and economic opportunities in the region.”

Velesco will be the first life sciences tenant of the Quincy Center for Innovation, a 12,500 square foot facility providing inexpensive and flexible office space and support services to assist start-up companies and aspiring entrepreneurs. The QCI is expected to open fully September 1st.

“One of the goals of the QCI is to provide a landing spot for those companies who are not yet located in Massachusetts, but have an interest and need to get acclimated to the region before choosing a permanent location,” said Donna Mavromates, Director of the Quincy Center for Innovation.

“Our economic future depends so much on creative partnerships, and I am thrilled that work done together by the Quincy Chamber, ENC, and the City has secured a first life science company at our innovation center with the kind of reputation for ingenuity as Velesco,” said City of Quincy Mayor Thomas P. Koch. “This is a tremendous first step, and I very much look forward to watching the innovation center continue to grow.”

“We will continue our focus on drug formulation, analytical method development and the supply of cGMP clinical supplies to early phase clinical trials while maintaining an evolving understanding of our clients needs. The Quincy Center for Innovation’s emphasis on working with young vibrant companies makes this location an excellent fit for Velesco.”

“We are excited to see Velesco expand their footprint here in Massachusetts by building out a presence where their clients and potential clients are doing business,” said Robert K. Coughlin, president & CEO of MassBio, the life sciences trade association. “Contract research and manufacturing is a vital piece of the new drug development paradigm and we are proud to be a hub for the world’s leading contract organizations.”

“We are thrilled to welcome Velesco to the fast-growing Massachusetts life sciences community,” said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center, the quasi-public agency tasked with implementing the state’s 10-year, $1-billion Life Sciences Initiative. “The company is a welcome addition, and we are pleased that Velesco selected Massachusetts as the best place for its new business development office. We are confident that Velesco, as a contract research and manufacturing organization, will find in Massachusetts the partners and client base they need to be successful.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!